aripiprazole + duloxetine + mirtazapine + nortriptyline

This is a combination of four pharmaceutical drugs—aripiprazole, duloxetine, mirtazapine, and nortriptyline—each with distinct mechanisms of action primarily used in the management of psychiatric disorders such as depression and related conditions. - **Aripiprazole** is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors. It is approved for use in schizophrenia, bipolar disorder, and as adjunctive therapy in major depressive disorder. - **Duloxetine** is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant that increases levels of serotonin and norepinephrine by inhibiting their reuptake into neurons. It is indicated for major depressive disorder, generalized anxiety disorder, neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. - **Mirtazapine** is a tetracyclic antidepressant that enhances central noradrenergic and serotonergic activity by antagonizing central presynaptic alpha-2 adrenergic inhibitory autoreceptors and heteroreceptors; it also blocks certain serotonin receptors (notably 5-HT2/3) while acting as an antagonist at histamine H1 receptors. It is mainly used to treat major depressive disorder. - **Nortriptyline** is a tricyclic antidepressant (TCA) that inhibits the reuptake of norepinephrine (and to some extent serotonin), increasing their synaptic concentrations; it also has anticholinergic properties. Nortriptyline treats depression but may be used off-label for neuropathic pain or other indications. The combination does not have a unique brand name or established fixed-dose formulation on the market but may be prescribed off-label in complex cases where multiple mechanisms are targeted simultaneously for treatment-resistant depression or comorbid psychiatric conditions.